Prophylactic administration of granulocyte colony-stimulating factor when monocytopenia appears lessens neutropenia caused by chemotherapy for lung cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 23, Issue 3, 2000, Pages 278-282

  Oshita, Fumihiro ^a   Yamada, Kouzo ^a   Nomura, Ikuo ^a   Tanaka, Gaku ^a   Ikehara, Mizuki ^a   Noda, Kazumasa ^a  

^a KANAGAWA CANCER CENTER   (Japan)

Author keywords

Cisplatin; G CSF; Hematologic toxicity; Platinum

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; NEDAPLATIN; VINCRISTINE; VINDESINE;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; FEMALE; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NEUTROPENIA; PROPHYLAXIS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CISPLATIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKOCYTE COUNT; LEUKOPENIA; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA;

EID: 0034443899     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200006000-00014     Document Type: Article

References (16)

1. The frequency and management of infectious episodes and sepsis in small cell lung cancer patients receiving intensive chemotherapy with granulocyte-colony stimulating factor
2. Unexpected high toxicity in a phase II study of teniposide (VM-26) in elderly patients with untreated small cell lung cancer (SCLC)
3. Prospective evaluation of the feasibility of cisplatin-based chemotherapy for elderly lung cancer patients with normal organ functions
4. Early monocytopenia after chemotherapy as a risk factor for neutropenia
5. Toxicity grading criteria of the Japan Clinical Oncology Group
6. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer
7. Effect of recombinant human granulocyte macrophage colony-stimulating factor on chemotherapy-induced myelosuppression
8. Mode of action of human urinary colony-stimulating factor
9. Interleukin-4 induces secretion of CSF for granulocytes and CSF for macrophages by peripheral blood monocytes
10. Comparative effects in vivo of recombinant murine interleukin 3, natural murine colony-stimulating factor-1, and recombinant murine macrophage colony-stimulating factor on myelopoiesis in mice
11. In vivo hematologic effects of recombinant human macrophage colony-stimulating factor
12. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer
13. Dose-intensive chemotherapy in extensive-stage small cell lung cancer
14. Received dose-intensity: A randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer
15. Dose-ranging study of recombinant human granulocyte colony-stimulating factor in small-cell lung carcinoma
16. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy